Cerave Developed With Dermatologists Itch Relief Moisturizing

Pramoxine Hydrochloride


L'oreal Usa Products Inc
Human Otc Drug
NDC 49967-970
Cerave Developed With Dermatologists Itch Relief Moisturizing also known as Pramoxine Hydrochloride is a human otc drug labeled by 'L'oreal Usa Products Inc'. National Drug Code (NDC) number for Cerave Developed With Dermatologists Itch Relief Moisturizing is 49967-970. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Cerave Developed With Dermatologists Itch Relief Moisturizing drug includes Pramoxine Hydrochloride - 1 mg/mL . The currest status of Cerave Developed With Dermatologists Itch Relief Moisturizing drug is Active.

Drug Information:

Drug NDC: 49967-970
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Cerave Developed With Dermatologists Itch Relief Moisturizing
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Pramoxine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: L'oreal Usa Products Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:PRAMOXINE HYDROCHLORIDE - 1 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 17 Aug, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 02 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:L'Oreal USA Products Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0301871970080
UPC stands for Universal Product Code.
UNII:88AYB867L5
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
49967-970-01237 mL in 1 BOTTLE, PUMP (49967-970-01)17 Aug, 2017N/ANo
49967-970-0215 BOTTLE in 1 TRAY (49967-970-02) / 29.6 mL in 1 BOTTLE17 Aug, 2017N/ANo
49967-970-03473 mL in 1 BOTTLE (49967-970-03)17 Aug, 2017N/ANo
49967-970-04562 mL in 1 BOTTLE (49967-970-04)17 Aug, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic

Product Elements:

Cerave developed with dermatologists itch relief moisturizing pramoxine hydrochloride pramoxine hydrochloride pramoxine water isopropyl myristate cetyl alcohol stearic acid cetostearyl alcohol glyceryl monostearate peg-100 stearate glycerin dimethicone niacinamide ceramide 3 ceramide 6 ii ceramide 1 hyaluronic acid phenoxyethanol xanthan gum behentrimonium methosulfate polyglyceryl-3 diisostearate sodium hydroxide alcohol allantoin ethylhexylglycerin sodium lauroyl lactylate arginine pyroglutamate edetate disodium potassium phosphate, monobasic potassium phosphate, dibasic tasmannia lanceolata fruit zinc citrate sodium pyrrolidone carboxylate phytosphingosine cholesterol carbomer homopolymer type a (allyl pentaerythritol crosslinked) .alpha.-tocopherol acetate

Indications and Usage:

Use for the temporary relief of itching associated with minor skin irritations.

Warnings:

Warnings for external use only when using this product do not get into eyes stop use and ask a doctor if ▪ condition worsens ▪ symptoms last more than 7 days or clear up and occur again within a few days do not use on ▪ deep or puncture wounds ▪ animal bites ▪ serious burns keep out of reach of children. if swallowed, get medical help or contact a poison control center immediately.

Do Not Use:

Warnings for external use only when using this product do not get into eyes stop use and ask a doctor if ▪ condition worsens ▪ symptoms last more than 7 days or clear up and occur again within a few days do not use on ▪ deep or puncture wounds ▪ animal bites ▪ serious burns keep out of reach of children. if swallowed, get medical help or contact a poison control center immediately.

When Using:

When using this product do not get into eyes

Dosage and Administration:

Directions adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily children under 2 years of age: consult a doctor.

Stop Use:

Stop use and ask a doctor if ▪ condition worsens ▪ symptoms last more than 7 days or clear up and occur again within a few days do not use on ▪ deep or puncture wounds ▪ animal bites ▪ serious burns

Package Label Principal Display Panel:

Image of a label

Image of a label

Further Questions:

Questions? toll-free number 888-768-2915 www.cerave.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.